Rheumatoid Arthritis Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drugs Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Disease Modifying Anti-Rheumatic Drugs (DMARDs)), By Treatment (Synovectomy, Tendon Repair, Joint Fusion), By End User (Hospitals, Diagnostic Centers, Ambulatory Surgical Centers), and Region Forecast 2020-2031

Wound Debridement Market size was valued at US$ 26.5 billion in 2024 and is expected to reach US$ 39.7 billion by 2031, growing at a significant CAGR of 5.9% from 2025-2031. Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints. In RA, the body's immune system mistakenly attacks its own joint tissues, leading to inflammation, pain, stiffness, and potential joint damage over time. This condition can affect people of all ages but is more common in middle-aged and older adults, and it often affects multiple joints simultaneously. The goal of RA treatment is to manage symptoms, prevent joint damage, improve joint function, and enhance the patient's quality of life. Treatment approaches typically involve a combination of medications, lifestyle modifications, and in some cases, surgery.

The increasing prevalence of rheumatoid arthritis (RA) plays a pivotal role in driving the revenues of the market. As RA becomes more prevalent globally, with millions of people affected by this autoimmune disease, there is a growing demand for effective treatments to manage its debilitating symptoms. The aging population, coupled with lifestyle factors, contributes to the rise in RA cases. This surge in patient numbers creates a larger pool of individuals seeking medical care and therapies to alleviate pain, reduce inflammation, and prevent joint damage.

Advancements in treatment options are a significant driving force behind the growth of the market. Continuous research and innovation have led to the development of newer and more effective medications and therapies for managing RA. Biologics, targeted therapies, and advanced disease-modifying antirheumatic drugs (DMARDs) offer superior symptom control, reduced side effects, and improved outcomes compared to traditional treatments. These innovative options not only enhance the quality of life for RA patients but also encourage more individuals to seek early diagnosis and treatment initiation, as they have greater confidence in the effectiveness of these therapies. However, high costs associated with biological DMARD therapies may hinder the growth of the market over future years. Meanwhile, increased healthcare spending and improved access to medical care in many regions create significant opportunities for the development of the market. Key market players are developing innovative treatment solutions to further contribute to the market growth. For example, in September 2021, Lupin launched the authorized generic version of duexise (ibuprofen and famotidine) tablets of Horizon Medicines LLC in the US market. 

 Key Developments:       

• In February 2021, Pfizer partnered with Imcyse for the potential treatment of rheumatoid arthritis (RA) via Imcyse’s RA program based on its Imotope technology
• In June 2018, Eli Lilly and Company and Incyte Corporation announced the U.S. Food and Drug Administration (FDA) approval of 2-mg dose of OLUMIANT (baricitinib), for the treatment of active rheumatoid arthritis (RA).